

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/73318 A1

- (51) International Patent Classification⁷: **C07H 21/00**, 21/04
- (74) Agent: **SADOFF, B., J.**; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).
- (21) International Application Number: **PCT/US00/14527**
- (22) International Filing Date: **26 May 2000 (26.05.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/136,772 **28 May 1999 (28.05.1999)** **US**
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US **60/136,772 (CIP)**
Filed on **28 May 1999 (28.05.1999)**
- (71) Applicant (for all designated States except US): **BIO SCIENCE CONTRACT PRODUCTION CORPORATION** [US/US]; 5901 East Lombard Street, Baltimore, MD 21224 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **RAMASUBRAMANYAN, Natarajan** [IN/US]; 5901 East Lombard Street, Baltimore, MD 21224 (US).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/73318 A1

(54) Title: METHODS OF DNA PURIFICATION AND PURIFIED DNA

(57) Abstract: The present invention provides methods for the purification of plasmid DNA that includes removal of host cell impurities, such as endotoxins, RNA, proteins, and chromosomal DNA, from an aqueous solution containing plasmid DNA and methods for separation and purification of supercoiled plasmid DNA from an aqueous solution containing a mixture of supercoiled and nicked or relaxed plasmid DNA using hydrophobic interaction chromatography supports.

METHODS OF DNA PURIFICATION AND PURIFIED DNA

This application claims benefit of US. Provisional Application No. 60/136,772, filed May 28, 1999, the entire contents of which is incorporated
5 herein by reference.

The present invention provides methods for the purification of plasmid DNA that includes removal of host cell impurities, such as endotoxins, RNA , proteins and host cell DNA, from an aqueous solution containing plasmid DNA and methods for separation and purification of supercoiled plasmid DNA
10 from an aqueous solution containing a mixture of supercoiled and nicked or relaxed plasmid DNA using hydrophobic interaction media. Also provided are improved methods for small-scale, such as laboratory or bench-scale, purification of DNA and equipment used in such methods. The present invention provides purified and/or separated DNA, such as plasmid, preferably
15 supercoiled, DNA.

Gene therapy offers a new treatment paradigm for curing human disease. The use of DNA for treatment of genetically caused diseases, including cystic fibrosis, various types of cancer, etc., and immunization against diseases, is a promising mode of therapy that is currently being widely
20 pursued. Rather than altering the disease phenotype by using agents which interact with gene products, or are themselves gene products, gene therapy can theoretically modify specific genes resulting in disease cure or treatment. Gene therapy could also be used as a drug delivery system. To accomplish this, a gene that produces a useful product (RNA, peptide, protein, etc.) or is itself a
25 useful product (such as in the use of antisense DNA) would be inserted into the DNA or cell of a homologous, heterologous or autologous cell of an individual or host cell to be later administered to an individual, either *in vivo*, *ex vivo* or *in vitro*. For example, during blood vessel surgery, a gene that makes an anticlotting factor could be inserted into the DNA of cells lining

blood vessels to help prevent dangerous blood clots from forming. Many other conditions might also lend themselves to treatment using this general approach.

Gene therapy is expected to be a powerful tool for treating many of the more than 4,000 known genetic disorders, including cystic fibrosis, heart disease, cancer, arthritis, and other illnesses. Gene therapy generally requires the transfer of genetic material (DNA) into an individual. Gene delivery or the delivery of genetic material can be achieved either by direct administration of gene containing viruses or plasmid DNA to blood or tissues, indirectly through the introduction of cells manipulated in the laboratory to harbor foreign DNA or through various encapsulation or carrier techniques known in the art. Recent reports suggest direct delivery of DNA may also be possible. Several different systems are in use or under consideration for somatic gene transfer. These include, for example, DNA (either naked or complexed), RNA viruses (retroviruses), and DNA viruses (adenovirus, adenoassociated virus [AAV], herpes virus, and poxvirus).

The key advantages of non-viral mode of gene therapy, such as the use of plasmid DNA, is the ease of preparation in large quantities, a great degree of safety, a general lack of integration of the heterologous DNA into the host cell DNA, and the possibility of using gene(s) or gene(s) fragments of virtually unlimited size and number. Further, the use of plasmid DNA in gene therapy does not generally involve the use of extraneous gene(s) or proteins which may induce an unwanted immune response in the recipient. In addition, alternatives to the use of plasmid DNA, such as viral vectors, are relatively more expensive to produce.

Methods currently used to produce plasmid DNA generally provide a mixture of supercoiled plasmid DNA and a nicked (or relaxed) DNA artifact, which is generally not useful in the final application of the plasmid DNA. The methods of the present invention provide a non-destructive separation of

supercoiled and nicked plasmid DNA such that while the present methods are exemplified by recovery and use of the supercoiled plasmid DNA, one of ordinary skill will appreciate that either separated form of the plasmid DNA may be considered a useful product of the presently disclosed methods.

5 Moreover, while the present disclosure emphasizes the need for greater purity of supercoiled plasmid DNA in the context of gene therapy, one of ordinary skill in the art will appreciate that plasmid DNA is widely used in recombinant molecular biology beyond the use in gene therapy preparations and the presently disclosed invention finds wide applicability as a preparative method
10 for isolated and purified supercoiled plasmid DNA.

Currently available methods for separation of the two forms of plasmid DNA utilize ion exchange chromatography (A novel, rapid process for purification of plasmids for gene therapy (Bhikhabhai R. Ollivier M. and Blanche F., Amersham Pharmacia Biotech R & D, 75184 Uppsala, Sweden
15 and RPR Gencell, Rhone-Poulenc Roer, Center de Recherche de Vitry-Alfortville, 13 quai Jules Guesde, 94400 Vitry sur Siene, France. Publication number: 18-1129-51; Preparative purification of supercoiled plasmid DNA using anion exchange chromatography, Duarte Miguel Prazeres, Thomas Schleup, Charles Cooney, Journal of Chromatography A, 606 (1998),
20 31-45) or size exclusion chromatography (Prazeres, D.M., A comparison of Gel Filtration Chromatographic Supports for Plasmid Purification, Biotechnology Techniques Vol. 11, No. 6, June 1997, p 417-420), coupled with the use of additives such as polyethylene glycol (PEG), detergents, and other components such as hexamine cobalt, spermidine, and
25 polyvinylpyrrolidone (PVP). Recently a patent was awarded (Horn, et al (U.S. Patent No. 5,707,812)) for the purification of supercoiled plasmid DNA using PEG as an additive. However, currently known methods are unable to provide an efficient and cost effective separation of supercoiled and nicked (or relaxed) DNA. In addition, many of the known methods suffer from the disadvantage

of using PEG or other additives, which may not be desired in manufacture of plasmid DNA, as they require additional separation, disposal and quality control methods, which can be difficult, more time consuming and more expensive.

5 Alternative forms of known methods for separation of supercoiled and relaxed forms of plasmid DNA utilize very expensive, proprietary resins, which also utilize solvents, such as acetonitrile, ethanol and other components, like triethylamine and tetrabutyl ammonium phosphate, during processing. These methods are generally not suited for large-scale production due to the
10 use of solvents. Moreover, they cannot be applied to starting materials that have significant amount of relaxed plasmid DNA as the abundant amount of contaminating relaxed plasmid DNA in starting materials tends to reduce the resolution capabilities of these resins. (Green, A. P. et al. Bio. Pharm. Vol. 10, No. 5, pages 52-62, May 1997.)

15 Additional methods of separating supercoiled and relaxed DNA rely on size-exclusion chromatography, which involves separation of the two forms of plasmid DNA based on the small difference in size. These columns tend to be relatively long, posing significant scale-up problems, making it infeasible to implement in large-scale production. In addition size-exclusion methods need
20 concentrated sample solutions, that are infeasible to obtain with plasmid DNA solutions, due to the highly viscous nature of the DNA. See, A comparison of gel filtration chromatographic supports for plasmid purification G.N.M. Ferreira, J.M.S. Cabral and D.M.F. Prazeres, Biotechnology Techniques, Volume 11, No. 6, June 1997, pp 417-420.

25 Plasmid DNA preparations, which are produced from bacterial preparations and often contain a mixture of relaxed and supercoiled plasmid DNA, often requires endotoxin removal, as required by the FDA, as endotoxins produced by many bacterial hosts are known to cause inflammatory reactions, such as fever or sepsis in the host receiving the plasmid DNA.

These endotoxins are generally lipopolysacchrides, or fragments thereof, that are components of the outer membrane of Gram-negative bacteria, and are present in the DNA preparation as artifacts of the hosts cells or as a part of larger artifacts, such as host cell membranes or macromolecules, used in expression and manufacture of the plasmid DNA for gene therapy, for example. Hence removal of endotoxins is a crucial and necessary step in the purification of plasmid DNA for therapeutic or prophylactic use.

Endotoxin removal from plasmid DNA solutions primarily have used the negatively charged structure of the endotoxins; however plasmid DNA also is negatively charged and hence separation is usually achieved with anion exchange resins which bind both these molecules and, under certain conditions, preferentially elute plasmid DNA while binding the endotoxins. Such a separation results in only partial removal as significant amounts of endotoxins elute with the plasmid DNA and/or a very poor recovery of plasmid DNA is achieved. Other patented methods use detergents, which could pose problems. (Process for the depletion or removal of endotoxins, Coplan, Metin, Moritz, Peter, Schorr, Joachim, U.S. Patent Number: 5,747,663.) In addition, the binding capacity of these resins is only on the order of 10^3 to 10^4 EU (endotoxin units) /ml of resin as the resin is occupied by both endotoxin and plasmid DNA, for example, typically requiring 3 to 80 liters of resin, based on reported capacities of 50,000 EU/ml to 2000 EU/ml (Green, A. P. et al. Bio. Pharm. Vol. 10, No. 5, pages 52-62, May 1997. Sterogene technical profile DNA Etox, Sterogene, 5922 Farnsworth Cr., Carlsbad, CA 92008).

The present invention provides methods of plasmid DNA separation, isolation and/or purification which may be used in combination or independently. Specifically, the present invention provides methods of separation, purification and/or isolation of supercoiled and relaxed plasmid DNA as well as methods of separation, purification and/or isolation of plasmid

DNA from host cell impurities, such as endotoxin containing components or fragments. Purified, separated and/or isolated plasmid DNA, specifically supercoiled plasmid DNA, compositions are also provided by the present invention. The present invention also provides methods and apparatus for
5 laboratory- or bench-scale separation, isolation and/or purification of plasmid DNA.

The present invention provides methods for isolating desired types of polynucleotides from other components present in mixtures containing these polynucleotides, yielding compositions enriched in the desired type of
10 polynucleotides. The methods include the separation of the polynucleotides from the undesired components by contacting mixtures containing the polynucleotides with hydrophobic interactive media. The separation of the polynucleotides from other components, as well as the separation of types of polynucleotides results from the differing affinities of the polynucleotides and
15 other undesired components for the hydrophobic interactive media under differing ionic conditions. Thus, in the methods of the invention a hydrophobic interactive media is used that has a highly preferential binding for lipopolysaccharides and lipoproteins relative to polynucleotides; this preferential binding occurs over the range of ionic conditions used in the
20 separation process. Also included in the invention are methods that separate supercoiled DNA and relaxed DNA. The methods utilize ionic conditions wherein the supercoiled DNA binds preferentially to the hydrophobic interactive media relative to the relaxed DNA.

It is understood that, when describing a salt concentration used in the
25 methods of this invention, that an equivalent ionic strength of a different salt may be used. It is also understood that, especially with respect to methods which deplete and/or eliminate endotoxin, these methods apply to plasmid as well as non-plasmid DNA.

It is an object of the present invention to provide methods of plasmid DNA separation, isolation and/or purification from contaminating host cell impurities.

It is another object of the present invention to provide methods of
5 separation, purification and/or isolation of plasmid DNA and endotoxin containing components or fragments.

It is yet another object of the present invention to provide methods of separation, purification and/or isolation of supercoiled and relaxed plasmid DNA.

10 Purified, separated and/or isolated plasmid DNA, specifically supercoiled plasmid DNA, compositions are also provided by the present invention.

In one embodiment, the present invention provides a method of separating endotoxin and other host cell impurities (i.e., RNA, chromosomal
15 DNA, protein) from plasmid DNA involving contacting a cell lysate with a hydrophobic interaction media under conditions where the endotoxin and other contaminating substances bind to the hydrophobic interaction media to form a complex and separating the plasmid DNA and the complex. The endotoxin separated in the method of this embodiment includes endotoxin
20 from Gram-negative microorganisms as well as fragments and cellular and subcellular components bound to these endotoxins and endotoxin fragments. The hydrophobic interaction medium also binds RNA, including t-RNA, r-RNA and m-RNA, host cell proteins and chromosomal DNA. The hydrophobic interaction media useful in the present invention may be in the
25 form of resins, membranes or other support media.

A preferred form of this embodiment includes loading of the mixture of plasmid DNA, with optional other contaminating host cell components, including endotoxin, being present, on a column or bed matrix containing the hydrophobic interaction media, in a manner where the endotoxin and host cell

impurities preferentially binds or is retained by the hydrophobic interaction media, and the plasmid DNA is collected as effluent (flow-through) from the loading process or in optional subsequent washing(s) of the hydrophobic interaction media which do not disturb or disrupt the retention of the host cell
5 impurities and endotoxin on and/or in the hydrophobic interaction media. After collection of the plasmid DNA, the column or bed matrix may be regenerated by eluting bound or retained host cell impurities and endotoxin by altering, changing or modifying the hydrophobic interaction conditions of the column or bed by, for example, altering the salt concentration surrounding the
10 column or bed matrix.

Alternate embodiments of the present invention provide methods of separation in the absence of either or both ion exchange chromatography or size exclusion chromatography.

In one preferred form of this embodiment, the column or bed volume is
15 initially equilibrated with an ammonium sulfate reaction solution at a concentration which allows selective binding of the contaminating impurities to the hydrophobic interaction column, preferably, a concentration of about 2M. Salts which may be used in the method of the present invention include mixtures of anions and cations selected from the group consisting of, but not
20 limited to, acetate, phosphate, carbonate, SO_4^{2-} , Cl^- , Br^- , NO_3^- , Mg^{2+} , Li^+ , Na^+ , K^+ , NH_4^+ . Mixtures of salts may be used. Moreover, the mixture of plasmid DNA and other contaminating impurities, such as endotoxin, are preferably dialyzed with a dialysis buffer prior to contacting with the column or bed matrix to remove salts and other contaminants which may alter the
25 hydrophobicity of the endotoxin and plasmid DNA and other contaminating impurities, such as endotoxin, in the ammonium sulfate reaction solution. The reaction solution is preferably buffered with, for example, Tris-HCl at a pH in the range of, but not limited to, 6.8 to 8.5, preferably 7.4. Other buffers, are known to those skilled in the art, such as, but not limited to, Tris, TES (N-

tris(hydroxymethyl)methyl-2-aminoethane-sulfonic acid), Tricine (N-tris(hydroxymethyl) methylglycine), phosphate, PIPES (Piperazine-N,N'-bis(2-ethane sulfonic acid), MOPS (3-(N-morpholino)-propanesulfonic acid), MES (2-(N-morpholino)-ethanesulfonic acid), MEPES (3-N(N-Morpholino)ethylpiperazine-N'-2-ethanesulfonic acid), and Bicine (N,N-bis(2-hydroxyethyl) glycine) may be used.

The methods of the present invention provide isolated and/or purified plasmid DNA, and a composition containing the plasmid DNA, which has a substantially-reduced endotoxin content, or is endotoxin-free, such that the
10 endotoxin load of the plasmid DNA has been reduced by as much as greater than 95%, preferably, greater than 98%, more preferably greater than 99%, alternatively greater than 99.9% and most preferably greater than 99.99% to 99.999%. The method of the present invention may be used to separate large initial loads of endotoxin, such as at least 200,000 to 400,000 endotoxin units
15 (EU)/milliliter of solution, providing a capacity of at least 600,000 to 3 million EU/ml hydrophobic matrix. Moreover, the process of the present invention provides a product plasmid DNA composition containing a range of less than about 10 to less than about 2500 EU or a range of less than about 1 to less than about 300 EU/mg DNA. Alternatively, the process of the present invention
20 provides a product plasmid DNA composition containing a range of less than about 50 to less than about 1000 endotoxin units (EU) or a range of less than about 10 to less than about 50 EU/mg DNA. The method of the present invention also reduces protein content to less than 0.1% (w/w) RNA to less than 1% (w/w) and chromosomal DNA to less than 1% (w/w).

25 In another embodiment, the present invention provides a method of separating supercoiled plasmid DNA from relaxed plasmid DNA which includes the steps of contacting a mixture of supercoiled plasmid DNA and relaxed plasmid DNA with a hydrophobic interaction media under a first conditions where both the supercoiled plasmid DNA and the relaxed plasmid

DNA bind to the hydrophobic interaction media to form a bound first mixture, altering the first conditions surrounding the bound first mixture to a second conditions to remove the relaxed plasmid DNA from the bound first mixture to form separate components containing a second bound mixture and the relaxed plasmid DNA, and modifying the second conditions surrounding the second bound mixture to a third conditions to remove the supercoiled plasmid DNA from the second bound mixture to form separate components containing the hydrophobic interaction media and the supercoiled plasmid DNA.

10 In another form of this embodiment, the altering and modifying can be performed by changing the pH conditions of the eluting buffer or solution, in such a way that the relaxed and supercoiled forms could be eluted at different pH conditions, with or without change in salt conditions.

15 In another form of this embodiment, the altering and modifying can be performed through isocratic elution, where a solution of the same composition, preferably at a salt concentration that can elute both forms of the plasmid DNA, when passed through the column containing the bound plasmid, would sequentially elute the two forms distinctly, in separate fractions.

20 In another embodiment, the salt conditions and/or other conditions can be modified in such a way that the relaxed form of the plasmid could be collected as the unbound fraction, while the supercoiled form binds to the resin. The supercoiled form can subsequently be eluted by using conditions outlined above.

25 In another form of this embodiment, the altering and modifying can be performed by use of molecules or a mixture of molecules that competitively bind to the ligands ("displacers") and remove the bound plasmid DNA forms from the matrix as separate components.

In another form of this embodiment, molecules or mixture of molecules that can bind through hydrophobic interaction or otherwise, can be

mixed with plasmid DNA solutions, which, on loading on to the column could be sequentially displaced, resulting in separation of the different forms of DNA.

In the above two alternative forms of the embodiment, commonly referred to as "displacement" and "frontal" mode of chromatography, the added molecule may co-elute with the product which, in most cases can be effectively separated using methods known to those in the art.

Displacement chromatography is a mode of chromatography in which two or more molecules bound to a resin are displaced using a displacer molecule that has higher affinity for the resin resulting in sequential displacement and hence elution of the two or more bound molecules. Recently, displacers for hydrophobic interaction resins have been identified, which consists of triblock copolymers including polymethyl methacrylate, acrylic acid, and polydimethylaminoethyl methacrylate (see Ruaan et al "Hydrophobic displacement chromatography of proteins using triblock copolymers as displacers, 1998 AIChE meeting). Other displacers have been successfully developed for displacement chromatography with hydrophobic interaction resins (see Shukla et. al. Hydrophobic displacement chromatography of proteins in 1998 Annual AIChE meeting). Displacers such as 2-(2-butoxyethoxy)ethanol have been used as displacers in reverse phase chromatography, which might be useful.

After binding the two forms of the plasmid, a displacer, such as ones listed above could be used to displace supercoiled and relaxed DNA sequentially from the HIC (hydrophobic interaction column) resins described herein.

In "Frontal" mode of chromatography, the column is loaded with a binary mixture, differing in their affinity for the resin, and upon continually overloading the column, one component displaces the other and results in sequential elution of the two components. In the application of this method for

the current invention, the two forms of DNA, for example, could be loaded on a HIC column and overloading of the sample could result in displacement effect leading to the displacement of the relaxed form, which can be collected separately from the supercoiled form.

5 In one form of this embodiment, the altering and modifying are combined in a continuous process of a gradient elution of the relaxed plasmid DNA and supercoiled plasmid DNA by mixing the bound first mixture with a salt solution, such as ammonium sulfate solution, with a continuously varying concentration of salt, such as ammonium sulfate, the concentration preferably
10 varying from about 3M to about 1 M salt, such as ammonium sulfate. The relaxed plasmid DNA is collected in this form of this embodiment of the invention in a first eluted volume and the supercoiled plasmid DNA is collected in a second eluted volume.

 In another preferred form of this embodiment, the supercoiled and
15 relaxed forms of the plasmid DNA are separated by first binding both forms of the DNA to a hydrophobic interaction media in a bed or column at high salt concentrations, or equivalent ionic strengths, such as 2.5 M to 4 M, preferably 3 M, ammonium sulfate, and then eluting, either in a step gradient or continuous gradient manner, the two separate forms of the plasmid DNA off
20 the column, by changing the salt concentration, or equivalent ionic strengths, to a first range of about 2.45 M to about 2.35 M ammonium sulfate and then to a second range of about 0 M (possibly 1 M) to about 2.3 M ammonium sulfate (in the step elution embodiment) or by continuously changing the ammonium sulfate concentration from the range of about 2.5 M to about 4M to a second
25 range of about 0 M (possibly 1 M) to about 2.3 M over a volume of about 1 to about 30 column or bed volumes, preferably at least 6 column or bed volumes (in the continuous gradient embodiment). In each of these forms, the relaxed plasmid DNA elutes from the column or bed media at a salt (ammonium sulfate) concentration in the range of about 2.35 M to about 2.45 M whereas

the supercoiled plasmid DNA elutes from the column or bed media at a salt (ammonium sulfate) concentration in the range of about 0M to about 2.3 M.

In another embodiment, the invention provides methods of isolating supercoiled plasmid DNA which includes:

5 applying a sample containing supercoiled plasmid to a hydrophobic interaction media under ionic conditions whereby the supercoiled plasmid preferentially binds to the media with respect to non-supercoiled plasmid; and
 adjusting the ionic conditions such that bound supercoiled plasmid is removed from the media.

10 In another preferred embodiment, the present invention provides a method for the enriching the amount of supercoiled DNA relative to relaxed DNA in a mixture thereof, the method including (1) interacting the mixture containing supercoiled DNA and relaxed DNA with a hydrophobic interactive media containing an alkyl moiety under ionic conditions wherein
15 the supercoiled DNA preferentially binds to the hydrophobic interactive media; (2) treating the hydrophobic interactive media containing the relaxed and supercoiled DNA under ionic conditions that allow the preferential removal of the relaxed DNA; and (3) eluting the supercoiled DNA from the hydrophobic interactive media.

20 In a further preferred embodiment, the present invention provides a method for removing lipopolysaccharide (LPS) from a composition containing DNA, the method including the steps of (1) interacting the mixture containing the DNA and LPS with a hydrophobic interactive media containing an alkyl moiety, wherein the interacting is under ionic conditions where the
25 LPS preferentially binds to the hydrophobic interactive media relative to the DNA; and (2) treating the hydrophobic interactive media containing the DNA and LPS with ionic conditions that allow the selective removal of the DNA.

The methods of the present invention provide isolated and/or purified supercoiled plasmid DNA, and a composition containing the supercoiled

plasmid DNA, which is preferably endotoxin free, such that the amount of supercoiled plasmid DNA present in the composition produced by the presently disclosed methods is at least about 50% by weight of the total plasmid amount to at least about 99% by weight, preferably at least about 60% by weight to at least about 95% by weight, more preferably at least about 70% by weight to at least about 90% by weight, most preferably at least about 75% by weight to at least about 85% by weight, supercoiled plasmid DNA.

Weight percent may be measured, as exemplified herein, by HPLC resolution on a DNA-NPR HPLC column, through a gradient, resulting in peaks with areas corresponding to the amount of each component. The percentage of supercoiled form was calculated as the fraction of the peak area corresponding to supercoiled DNA to the total area of the supercoiled and relaxed plasmid DNA peaks.

Preferred hydrophobic interaction media which may be used in the methods of the present invention include hydrophobic interaction chromatography resins that, for example, contain methacrylate polymer or copolymer backbones, such as methacrylate /ethylene glycol and/or methacrylate/propylene glycol copolymers (TosoHaas, Montgomeryville, PA), and/or an agarose or Sepharose (Amersham Pharmacia Biotech, Piscataway, NJ), such as crosslinked or non-crosslinked, agarose, Sepharose, dextran, silica containing polymer, organic polymers (natural or synthetic), a ceramic-containing, or a gel matrix, backbone, or a combination of any of these, with C₃ to C₁₀ alkyl, branched or straight, pendent side chain ligands. Preferred pendent ligands include propyl, butyl, hexyl and/or octyl ligands. These ligands provide the preferential binding interaction which is exploited in the separation, purification and/or isolation methods of the present invention. One of ordinary skill in the art will appreciate that hydrophobic interaction resins may include ligands in addition to or in place of these alkyl ligands, which will also be useful in the method of the present invention. Examples of such

ligands include, but are not limited to, phenyl, octyl, butyl, propyl, neopentyl, hydroxypropyl, benzyl, octadecyl, diphenyl, and methyl as well as substituted and unsubstituted derivatives of same, and combinations thereof. Suitable resin or media materials useful in the present invention include those
5 described, for example, in EP Patent No. 964057, EP Application No. 99109441, JP 2000035423, JP 99127700 and JP 98127665 (Kitamura et al.) the entire contents of each of which are hereby incorporated by reference.

The hydrophobic interaction media may be in the form of beads, which may be packed or loaded into a column or bed reactor, or a crosslinked porous
10 media. The size of bead media may range from 2.5 μm to greater than or equal to 100 μm . The size of bead media is preferably in the range of about 30 to about 110 μm in diameter, such as about 35 to about 100 μm in diameter, or, alternatively in the range of 35 to 90 μm in diameter. The hydrophobic interaction media may be present in the form of membranes, such as cellulose
15 or cellulose derivative backbones, polyether sulfones, polysulfones, and derivatives of same and/or other materials known in the filtration and separation arts, including plastics, such as and including microtiter plates and petri or cell culture dishes and containers.

The beads used in "Streamline" (Amersham Pharmacia biotech)
20 columns typically are larger in size with different densities, and are made by various manufactures, including Amersham Pharmacia Biotech, Biosepra Inc, but not limited to these, where the clarified lysate could be flowed through these "expanded bed" columns, resulting in removal of contaminants through binding to the beads that contain the hydrophobic interactive ligands.

25 Smaller bead sizes, typically are used in high performance separations, including HPLC, where this invention can be utilized to provide a quantitative analytical method for plasmid DNA and/or different forms of DNA.

The beads for the purposes of use in this invention, particularly the separation of two forms of plasmid DNA does not need to be porous as the

plasmid DNA is generally too large to be able to occupy the pores, and hence provide any additional capacity. However, for the purposes of contaminant binding, pores could effectively increase capacity as the contaminant molecules such as RNA, protein, endotoxin and DNA fragments are
5 comparable or smaller than the size of pores. In this case porosity will play a role and hence porous resins may be useful.

The methods of the present invention preferably do not require organic solvents, or additives or detergents, such as glycols, polyethylene glycol hexamine cobalt, spermidine or polyvinyl pyrrolidone, which would later
10 require separation from the product supercoiled plasmid DNA prior to use in, for example, gene therapy.

Brief Description of the Drawings

15 Figure 1 shows a flow diagram of the various steps involved in performing the exemplified method of separating supercoiled and relaxed plasmid DNA.

Figure 2 shows a conceptual depiction of the various hydrophobic interaction supports with the ligand chemistries attached to them that were
20 used in the exemplified method.

Figure 3 shows a flow diagram of the various steps involved in performing the exemplified method of separating endotoxin from plasmid DNA.

Figure 4 (insert) shows a scanned image of an agarose gel from
25 Example 5 (butyl HIC) stained with SYBR GOLD wherein lane 1 contains a supercoiled DNA Ladder; lanes 2 and 3, contain samples from peak 1 (relaxed) and lanes 3-5 contain samples from peak 2 (supercoiled). (Lanes being numbered from left to right.) The chromatogram from Example 5 of

absorbance versus volume shows the separation of relaxed (peak 1) and supercoiled DNA (peak 2).

Figure 5 (insert) shows a scanned image of an agarose gel from Example 6 (butyl HIC) stained with SYBR GOLD wherein lane 1 contains a marker; lanes 2 and 3 contain samples from peak 1 (relaxed) and lanes 4-6 contain fractions from peak 2 (supercoiled form). (Lanes being numbered from left to right.) The chromatogram from Example 6 shows the separation of relaxed (peak 1) and supercoiled DNA (peak 2) forms.

Figure 6 (insert) shows a scanned image of an agarose gel from Example 7 wherein lane 1 contains a marker, lanes 2 and 3 contain material loaded on the column; lane 4 contains material from the artifact peak; lane 5 contains material from the 2.4M AS Elution; and lane 6 contains material from the 1M AS Elution. (Lanes being numbered from left to right.) The chromatogram shown separation of relaxed and supercoiled forms of plasmid DNA wherein the artifact peak is a broad first (left) peak, followed to the right by relaxed and supercoiled peaks, respectively.

Figure 7 (insert) shows a scanned image of an agarose gel from Example 8 (hexyl HIC) wherein lane 1 contains a marker; lanes 2-4 contain material from peak 1 (relaxed form); and lanes 5 and 6 contain fractions from peak 2 (supercoiled form). (Lanes and peaks numbered from left to right.) The chromatogram demonstrates the separation of relaxed from supercoiled forms.

Figure 8 shows a scanned image of an agarose gel electrophoresis of samples SYBR GOLD stained, from Example 9, wherein lane 1 is a marker; lane 2 contains the material loaded on the column; lanes 3, 4 and 5 contain the washes 1, 2 and 3, respectively; lane 6 contains the 1M elution; and lane 7 contains the water elution.

The methods of the present invention exploits the differences in hydrophobicities of supercoiled plasmid DNA, relaxed plasmid DNA and cellular contaminants, such as endotoxin.

The methods disclosed herein are useful for purifying and isolating
5 supercoiled plasmid DNA, cosmids, and phagemid vectors. These vectors and plasmid DNA could be purified from any source. In addition, plasmid DNA and cosmids present in yeast and mammalian cells can also be purified, as similar mixtures of contaminants, including endotoxins, RNA, proteins and chromosomal DNA, could be present in these preparations. There is also the
10 need to obtain supercoiled form of the plasmid and cosmid DNA from these sources and hence, the methods described herein could be used in purifying DNA in many of these applications.

"Hydrophobic interaction media" is a material comprising (a) a support moiety and (b) a hydrophobic moiety attached either directly or indirectly to
15 the support moiety. Examples of support moieties and hydrophobic moieties are described herein and are known in the art. The hydrophobic moiety provides the basis for preferential binding used in the separation methods described herein. Various examples of "hydrophobic interaction media" are known in the art and are described herein. Other terms used herein also denote
20 hydrophobic interaction media and examples thereof, such as "resin", "matrix", "column", "media", "beads" and "hydrophobic interaction ligand".

"DNA" means any form of deoxyribonucleic acid, including, but not limited to, plasmid (whether supercoiled and/or relaxed or nicked), cosmid, or artificial chromosome.

25 "Nicked" or "relaxed" DNA means DNA that is not supercoiled. "Supercoiled" DNA is a term well understood in the art.

A "contaminating impurity" is any substance from which it is desired to separate, or isolate, DNA. Contaminating impurities include, but are not limited to, host cell proteins, endotoxin, host cell DNA and/or RNA. It is

understood that, what is considered a contaminating impurity can depend on the context in which the methods of the invention are practiced. A "contaminating impurity" may or may not be host cell derived, i.e., it may or may not be a host cell impurity.

5 "Isolating" or "purifying" a first component (such as DNA) means enrichment of the first component from other components with which the first component is initially found. Extents of desired and/or obtainable purification are provided herein. Preferably, the methods of the invention result in an about five-fold enrichment, preferably an about 10-fold enrichment, preferably
10 an about 20 fold enrichment, preferably an about 50 fold enrichment, preferably an about 100 fold enrichment, preferably an about 200 fold enrichment, preferably an about 500 fold enrichment, preferably an about 1000 fold enrichment. Alternatively, the degree of purification may be expressed as a percentage of the first component with respect to another component, or with
15 respect to the resultant preparation. Examples of such percentages are provided herein.

"Preferential" or "selective" binding or removal of a component means that, for a given condition, the first component binds or is removed to a greater degree with respect to another component.

20 As would be understood by those skilled in the art, "removal" or "binding" does not necessarily, or even desirably, mean complete, or 100%, removal or binding.

An "aqueous" solution generally indicates a water-based solution (i.e., the main solvent is water), which may or may not be 100% water as solvent.

25 Isolation of plasmid DNA produced in recombinant bacterial cells involves lysis of the cells and removal of cellular debris, which can be accomplished through various methods. The final solution contains plasmid DNA, typically containing extremely high amounts of endotoxins among other contaminants. The methods of the present invention provides for the removal

of significant amounts of the key contaminants, such as RNA, genomic DNA, protein and endotoxin using hydrophobic interaction chromatography as a first step, where the plasmid DNA flows through unbound. A method of the present invention involves, optionally dialyzing the mixed solution
5 obtained from bacterial lysis into a buffer in the pH range of 6.8 to 8.5, preferably a pH of 6.8 to 7.4, containing, preferably, 2M ammonium sulfate, with or without 10mM ethylenediaminetetraacetic acid (EDTA), and flowing the optionally dialyzed solution through a packed chromatography column containing a chromatographic support with a hydrophobic interaction
10 ligand(s), such as any of, or a mixture of, a propyl, a butyl, octyl or hexyl ligand, which had, preferably previously been equilibrated with a buffer in the pH range of 6.8 to 8.5 (preferably 6.8 to 7.4), also containing 2M ammonium sulfate, with or without 10mM EDTA. The flow-through solution is typically at about a 2M concentration of salts, such as ammonium sulfate,
15 and predominantly contains plasmid DNA (mixture of supercoiled and relaxed) with less than 2% of contaminants. Depending on the variations in the upstream steps, the percentage of supercoiled DNA can range anywhere between 50 and 95% by weight, typically about 75 to 85%, alternatively, 80 to 85%, requiring further purification, involving the removal of the relaxed form
20 of plasmid DNA from the mixture.

Methods of the present invention also make it possible to produce purified plasmid DNA which have endotoxin levels below specified levels, i.e., typically <10 EU/mg plasmid DNA. The methods of endotoxin removal of the present invention are either adaptable to large-scale or small-scale
25 production, enabling economical production of therapeutic and laboratory grade material. These methods exploit the selective binding of endotoxin to the hydrophobic resins described herein which, for large-scale production, may contain capacities exceeding one million units per milliliter of resin used.

Conventionally available methods of endotoxin removal have low capacities (1,000 to 50,000 EU/milliliter of resin) and/or result in low plasmid DNA recoveries and/or involve use of chemical components and/or methods that cannot be readily used in preparation of therapeutic grade material. (U.S. Patent No. 5,747,663) The method of endotoxin removal of the present invention involves suspending the endotoxin- and plasmid DNA-containing solution in a salt, such as ammonium sulfate or sodium chloride at a concentration of about 2M which makes the endotoxin significantly more hydrophobic than the plasmid DNA and assures binding or preferential interaction and separation of the endotoxin on a resin containing hydrophobic interaction ligands, such as butyl, octyl, and/or hexyl groups, as compared with the plasmid DNA. The salt concentration used may preferably be optimized to bind RNA, protein and endotoxin. A lower salt concentration may be sufficient to provide endotoxin binding alone as endotoxin has a greater affinity for the hydrophobic interaction ligands described herein.

An attractive feature of this method of endotoxin removal is the immense capacity of the resin for the endotoxin, of approximately 1,000,000 EU/ml of resin, in addition to the simplicity and >95% recovery of plasmid DNA. For example, a plasmid DNA solution containing 500 mg of plasmid and 10 million EU of endotoxin can be purified using 10 ml of resin, whereas, at least 1,000 to 4,000 ml of an anion exchange resin would be required for binding the plasmid DNA and the endotoxin, with the added disadvantage of poor recoveries on such an anion exchange resin. The method of the present invention therefore results in savings of 100 to 400 fold in resin cost, and additional savings on column cost and increased recovery of product. The commercially available DNA Etox resin is currently at least 8 fold more expensive than the resins used in the method of the present invention. Another commercial resin (PolyFlo – PureSyn Inc., 87 Great Valley Pkwy Malvern, PA 19355) with proprietary chemistry that is useful in endotoxin removal is 5 to

10 fold more expensive and requires the use of solvents and ion-pairing chemicals.

The methods of the present invention provide high quality plasmid DNA comprising greater than 90% supercoiled plasmid DNA from starting material of lesser quality (i.e., a starting material composed of a mixture of relaxed and supercoiled DNA). Additionally, the methods of the present invention are applicable for large-scale processes typically used for production of plasmid DNA for gene therapy. The methods of the present invention enable reliable production of high quality plasmid DNA, independent of variations that typically lead to reduction in quality i.e. generation of relaxed/nicked form of plasmid DNA. These variations could occur during growth of the bacteria producing the plasmid DNA and subsequent isolation and purification steps.

The methods of separating supercoiled and relaxed plasmid DNA, and methods of separating plasmid DNA and endotoxin, of the present invention are based on a discovery that the forms of plasmid DNA and endotoxin exhibit different binding specificities on hydrophobic interaction chromatography resins that, for example, contain C₄ to C₁₀ alkyl, branched or straight, ligands, and preferably contain either a butyl or hexyl ligand. These ligands provide the preferential binding interaction which is exploited in the separation, purification and/or isolation methods of the present invention. One of ordinary skill in the art will appreciate that hydrophobic resins may include ligands in addition to or in place of these alkyl ligands, which will also be useful in the method of the present invention. Examples of such ligands are also described above. The following non-limiting examples illustrate the methods of the presently disclosed invention. The following general methods were or could be used.

Plasmids for gene therapy applications were extracted from a suitable host bacterium, for example *Escherchia coli*, following fermentation. In the

following exemplification of the disclosed invention, *E. coli* STBL-2, which contains plasmid pE1A-K2 was used. Plasmid pE1-A-K2 is a pUC plasmid derivative that contains a suppresser gene from adenovirus Type 5, and contains a kanamycin gene as a selectable marker. Fermentation was
5 conducted aerobically in a suitable yeast extract/glucose medium containing inorganic salts, such as potassium mono basic phosphate, sodium dibasic phosphate, ammonium sulfate and magnesium sulfate at a pH of from 6.5 to 7.8, preferably 7.0, and at a temperature of 37°C. Aeration was set to one volume of air per volume of medium and the agitation set to 800 rpm. Cells
10 were grown in this mode until the glucose was exhausted from the medium, then the DO of the fermentor was controlled by glucose feed and agitation. The feed contained a concentrated solution of glucose (160 g/L) and yeast extract (80 g/L) and salts (1.5 g/L ammonium sulfate, MgSO₄, 1.5 g/L in phosphate buffer). After completion of fermentation, the cells were harvested
15 by centrifugation or by filtration through ultra or microfiltration membranes, and washed with TE (see below) buffer, pH 7.4. Cells were lysed by contacting the suspension with an equal volume of a solution of 0.15N to 0.2N NaOH and 1% sodium dodecyl sulfate (pH 11.5 to 13) with gentle mixing. The alkaline solution was neutralized with a potassium acetate solution. The
20 material was then clarified by either centrifugation or by passing the suspension through a series of depth filters. Plasmid solutions are concentrated by ultrafiltration membranes and diafiltered against TE buffer, pH 7. The diafilter retentate can be applied directly to the media described herein.

The plasmid DNA content of the lysate is generally less than 2% of the
25 total nucleic acid with the bulk of the contents being RNA or chromosomal DNA. In addition, the lysate is contaminated with endotoxin and cellular proteins.

The present invention also provides methods of small-, laboratory- or bench-scale production of isolated or purified DNA, and equipment columns

and separators useful therein. One of ordinary skill in the art will appreciate that small-scale production of plasmid DNA introduces different challenges, as compared to large-scale production. Specifically, the small-scale separation entails separation of a larger proportion of contaminating RNA in the starting material, such that while the plasmid to RNA ratio in a large-scale starting material may be about 2% (wt/wt), as noted above, the small scale ratio is about 0.1% (wt/wt). Moreover, the culture volume of the small-scale samples are generally about 2 mL to about 2L, as opposed to about 5L to about 1000L in the large-scale separation. The small-scale separations of the present invention involve about 100 µg to about 1mg of plasmid with a reactor or column bed volume of about 1 to about 20 ml; usually in the range of about 10 ml to about 15 ml. The present invention provides therefore, efficient small-scale production of isolated and/or purified DNA, preferably supercoiled DNA, from impurities, such as endotoxin, RNA and relaxed DNA.

While various procedures are used in the present exemplification, one of ordinary skill will appreciate that other preparative methods and starting materials may be used in the presently disclosed invention.

Example 1: Endotoxin removal using Butyl Hydrophobic Interaction Chromatography (Small scale)

E. coli cells harboring the plasmid pE1A-K2 were grown, and lysed using chemical methods, and clarified through filtration methods. All buffers used throughout were filtered through 0.2 µm filter, and samples for endotoxin were stored in polystyrene sample tubes.

A diafiltration retentate (~ 400ml) was dialyzed into TE pH 7.4 (50mM Tris, 10mM EDTA adjusted to pH 7.4 with HCl) was used for the experiment. Ammonium sulfate (AS) as required to make the sample 2M was added to 100 ml of TE plus 2M AS, pH 7.4 buffer and partially dissolved. This

solution was added to the dialyzed sample to make a final volume of 575 ml, of which 475 ml was used for the experiment.

A Butyl 650S column (Butyl 650S resin from TosoHaas Inc., 156 Keystone Drive, Montgomeryville, PA 18936) of 2.6 cm diameter and 15 cm bed height, of approximately 75 ml bed volume was packed and equilibrated with TE buffer, pH 7.4, containing 2M AS. The sample was loaded at a flow rate of 5 ml/min. The flow through was collected, and samples were taken for analysis (DNA concentration, agarose gel, and endotoxin assay. Endotoxin assay was performed with spikes and samples were diluted appropriately to obtain PPC (Positive Product Control) recoveries in the range considered acceptable. Endotoxin concentrations were determined using the BioWhittaker Kinetic-QCL Chromogenic LAL assay as described in BW publication No. P50-650U-5, Kinetic-QCL Test Kit Manual. Following the sample load, TE containing 2M ammonium sulfate was flowed through the column, and collected and sampled. The column was subsequently washed with TE buffer - pH 7.4, USP purified water, and cleaned with 0.5N sodium hydroxide, and rinsed with >15 volumes of USP purified water. Endotoxin was present in each of these washes as shown below in Table 1. In addition to this outstanding endotoxin removal efficiency, significant amount of RNA, protein, and DNA fragments were removed, leaving the sample significantly purified.

Table 1

Sample	DNA conc. (mg/ml)	Endotoxin EU/ml	Total EU units	% Endotoxin	EU per Mg of DNA
Load	0.70	472,200	22,400,000	100	674,571
Flow through	0.38	1.64	771	0.003	4.31
Wash	0.56	7.48	1,196	0.005	13.42

Endotoxin capacity per ml of resin:

3 million

EU/ml

5 Endotoxin reduction in sample:

99.992%

Example 2: Endotoxin removal using Butyl Hydrophobic Interaction Chromatography (large scale)

10 *E. coli* cells harboring the plasmid pE1A-K2 was grown, and lysed
using chemical methods, and clarified through filtration methods.

The diafiltration retentate (~ 650ml) was dialyzed into TE pH 7.4
(50mM Tris, 10mM EDTA adjusted to pH 7.4 with HCl) and ammonium
sulfate required to make the sample 2M was added to 1200 ml of TE
15 containing 2M AS, pH 7.4 buffer and dissolved. The volume of this solution
was made up to 1300 ml. This solution was added to the dialyzed sample to
make a final volume of 1950 ml, and pH was adjusted to 7.4 using HCl.

A Butyl 650S column of 5 cm diameter and 15 cm bed height, of
approximately 275 ml bed volume was packed and equilibrated with TE
20 buffer, pH 7.4, containing 2M AS. The sample was loaded at a flow rate of 20
ml/min. The flow through was collected, and samples were taken for analysis
(DNA concentration, agarose gel, and endotoxin assay, as described above).
Following the sample load, TE containing 2M ammonium sulfate was flowed
through the column, and collected and sampled. The column was

subsequently washed with TE buffer - pH 7.4, USP purified water, and cleaned with 0.5N sodium hydroxide, and rinsed with >15 volumes of USP purified water. Endotoxin was present in each of these washes as shown below in Table 2. In addition to this extremely outstanding endotoxin removal efficiency, significant amount of RNA, protein, and DNA fragments were removed, leaving the sample significantly purified.

Table 2

Sample	DNA conc. (mg/ml)	Endotoxin EU/ml	Total EU	% Endotoxin	EU per mg of DNA
Load	1.59	271500	176,475, 000	100	170,754
Flowthrough + Wash	0.34	<0.5	1325	0.007	1.45

Endotoxin capacity per ml of resin: 0.64
million EU/ml
Endotoxin reduction in sample: 99.993%

Example 3: Endotoxin removal using Hexyl Hydrophobic Interaction Chromatography (Small scale)

E. coli cells harboring the plasmid pE1A-K2 was grown, and lysed using chemical methods, and clarified through centrifugation methods. The supernatant was dialyzed into a 20mM potassium phosphate buffer (20mM potassium phosphate monobasic solution combined with 20mM potassium phosphate dibasic in a proportion to obtain a pH of 6.8), pH 6.8 and ammonium sulfate required to make the sample 2M was added to 20 ml of

KPB (20mM potassium phosphate buffer) containing 2M AS, pH 6.8 buffer and dissolved. This solution was added to 5 ml of dialyzed sample to make a final volume of 25 ml and pH was adjusted to 6.8.

A Hexyl 650C (TosoHaas) column of 1.6 cm diameter and 4 cm bed height, of approximately 8 ml bed volume was packed and equilibrated with KPB, pH 6.8, containing 2M AS. The sample was loaded at a flow rate of 2 ml/min. The flow through was collected, and samples were taken for analysis (DNA concentration, agarose gel, and endotoxin assay, see above). Following the sample load, KPB containing 2M ammonium sulfate was allowed to flow through the column, collected and sampled. The column was subsequently washed with KPB pH 6.8, USP purified water, and cleaned with 0.5N sodium hydroxide, and rinsed with >15 volumes of USP purified water. Endotoxin was present in each of these washes as shown below in Table 3. In addition to this extremely outstanding endotoxin removal efficiency, significant amount of RNA, protein, and DNA fragments were removed, leaving the sample significantly purified.

Table 3

Sample	DNA conc. (mg/ml)	Endotoxin EU/ml	Total EU units	% Endotoxin	EU per Mg of DNA
Load	2.43	593500	29,675,000	100	244,238
Flow through + Wash	0.037	0.5	35	0.0001	14

20

Endotoxin capacity per ml of resin:

3.7 million

EU/ml

Endotoxin reduction in sample:

99.999%

**Example 4: Endotoxin removal using Octyl Hydrophobic
Interaction Chromatography (Small scale)**

E. coli cells harboring the plasmid pE1A-K2 was grown, and lysed
5 using chemical methods, and clarified through centrifugation methods as
described above. The supernatant was used for the experiment. Ammonium
sulfate required to make the sample 2M was added to 20 ml of TE plus 2M
AS, pH 7.4 buffer and dissolved. This solution was added to 10 ml of dialyzed
sample to make a final volume of 25 ml and pH was adjusted to 7.4.
10 An Octyl Sepharose 4 Fast Flow column (Amersham Pharmacia
Biotech, Piscataway, NJ) of 1.0 cm diameter and 10 cm bed height, of
approximately 8 ml bed volume was packed and equilibrated with TE, pH 7.4,
containing 2M AS. The sample was loaded at a flow rate of 2 ml/min. The
flow through was collected, and samples were taken for analysis (DNA
15 concentration, agarose gel, and endotoxin assay). Following the sample load,
TE containing 2M ammonium sulfate was flowed through the column,
collected and sampled. The column was subsequently washed with TE pH 7.4,
USP purified water, and cleaned with 0.5N sodium hydroxide, and rinsed with
>15 volumes of USP purified water. Endotoxin was present in each of these
20 washes as shown below in Table 4.

Table 4

Sample	DNA conc. (mg/ml)	Endotoxin EU/ml	Total EU units	% Endotoxin	EU per mg of DNA
Load	2.43	593500	59,350,000	100	244,238
Flow through + Wash	0.037	32	2240	0.004	280

Endotoxin capacity per ml of resin:

7.41

million EU/ml

5 Endotoxin reduction in sample:

99.996%

Example 5: Separation of the supercoiled and relaxed forms of the plasmid DNA using Butyl Hydrophobic Interaction Chromatography –

10 Gradient Elution

E. coli cells harboring the plasmid pE1A-K2 were grown, and lysed using chemical methods, and clarified through filtration methods, as described above. Gross purification of the plasmid DNA to eliminate major contaminants such as endotoxin, RNA, protein, chromosomal DNA, etc. was performed using butyl hydrophobic interaction chromatography, where, at a concentration of 2M Ammonium sulfate, the plasmid DNA flows through the column while the contaminants bind to the column (see above).

The flow through containing the plasmid DNA was dialyzed and processed on an anion exchange (Bio Septra) column that did not provide any additional purification. Processing through the Q anion exchange column and diafiltrations are not necessary to achieve the separation on the butyl column. The elution from the Q anion exchange column was diafiltered using a 30kD regenerated cellulose membrane (0.1m², Millipore Corporation). The dialyzed material was adjusted to 3M ammonium sulfate using solid ammonium sulfate.

A Butyl (Toyopearl Butyl 650S – TosoHaas) column of 2.6 cm diameter and approximately 15 cm height was packed at a flow rate of 15-20ml/min. The column was equilibrated with 3M ammonium sulfate in Tris – EDTA buffer pH 7.4. The sample was loaded at a flow rate of 5 ml/min. The
5 plasmid was bound to the column at 3M ammonium sulfate. The column was then washed with 2-3 column volumes of a 3M ammonium sulfate solution in buffer. The column was then eluted with a gradient of ammonium sulfate concentration from 3M to 1M over 6 bed volumes. During the gradient elution, two peaks resulted, the first peak containing the relaxed form of the
10 plasmid DNA, and the second peak containing the supercoiled form of plasmid DNA as evidenced in agarose gels of fractions (Figure 4A). The chromatogram is shown in Figure 4B. The results were further confirmed by an HPLC assay used to determine the percentage of the two forms (Table 5).

Within the limits of sensitivity of the assay, it was confirmed that the
15 second peak contained 85% supercoiled form, whereas the starting material only contained 50-60% supercoiled form. At least 90% of the starting supercoiled plasmid DNA was recovered. The resolution of the peaks were adequate to effect the separation, even with 15 cm column height. This demonstrates the effective separation of supercoiled and relaxed forms of the
20 plasmid using Butyl hydrophobic interaction chromatography. In addition to this excellent separation, residual amount of RNA, protein, and endotoxin could be removed resulting in product that meets the specifications for gene therapy.

Table 5

Sample	% Supercoiled
Starting material	63
Peak 1 Fraction	8
Peak 2 Fraction	83

Example 6: Separation of the supercoiled and relaxed forms of the plasmid DNA using Butyl Hydrophobic Interaction Chromatography – Gradient Elution Long column

E. coli cells harboring the plasmid pE1A-K2 were grown, and lysed using chemical methods, and clarified through filtration methods, as described above. Gross purification of the plasmid DNA to eliminate major contaminants such as endotoxin, RNA, protein, chromosomal DNA, etc. was performed using butyl hydrophobic interaction chromatography, where, at a concentration of 2M Ammonium sulfate, the plasmid DNA flows through the column while the contaminants bind to the column (see above). The flow through containing the plasmid DNA was dialyzed and processed on an anion exchange column that did not provide any additional purification. The elution from the Q column was diafiltered using a 30kD regenerated cellulose membrane. The dialyzed material was adjusted to 3M ammonium sulfate using solid ammonium sulfate, as described above in Example 5.

A Butyl (Toyopearl Butyl 650S – TosoHaas) column of 2.6 cm diameter and approximately 30 cm height was packed at a flow rate of 15-20ml/min. The column was equilibrated with 3M ammonium sulfate in Tris – EDTA buffer pH 7.4. The sample was loaded at a flow rate of 5 ml/min. The plasmid was bound to the column at 3M ammonium sulfate. The column was then washed with 2-3 bed volumes with a 3M ammonium sulfate buffer

solution. The column was then eluted with a gradient of ammonium sulfate concentration from 3M to 1M over 6 bed volumes. During the gradient elution, two peaks resulted, the first peak containing the relaxed form of the plasmid DNA, and the second peak containing the supercoiled form of plasmid DNA as evidenced in agarose gels of fractions (Figure 5A). The chromatogram is shown in Figure 5B. The results were further confirmed by an HPLC assay used to determine the percentage of the two forms (Table 6).

Within the limits of sensitivity of the assay, it was confirmed that the second peak contained 90% supercoiled form, whereas the starting material only contained 50% supercoiled form. Baseline resolution of the peaks was obtained with the longer column. This example clearly demonstrates the effective separation of supercoiled and relaxed forms of the plasmid using butyl hydrophobic interaction chromatography. In addition to this excellent separation, residual amounts of RNA, protein, and endotoxin could be removed resulting in product that meets the specifications for gene therapy.

Table 6

Sample	% Supercoiled
Starting material	53
Peak 1 Fraction 36	15
Peak 2 Fraction 47	83
Peak 2 Fraction 49	95
Peak 2 Fraction 52	91

Example 7: Separation of the supercoiled and relaxed forms of the plasmid DNA using Butyl Hydrophobic Interaction Chromatography – Step Elution Long column

E. coli cells harboring the plasmid pE1A-K2 were grown, and lysed using chemical methods, and clarified through filtration methods, as described above. Gross purification of the plasmid DNA to eliminate major contaminants such as endotoxin, RNA, protein, chromosomal DNA, etc. was performed using butyl hydrophobic interaction chromatography, where, at a concentration of 2M Ammonium sulfate, the plasmid DNA flows through the column while the contaminants bind to the column (see Example 1 above). The flow through and wash were pooled and concentrated using a 30kD ultrafiltration membrane using tangential flow filtration. The concentrated plasmid DNA was adjusted to 3M ammonium sulfate using solid ammonium sulfate.

A Butyl (Toyopearl Butyl.650S – TosoHaas) column of 1 cm diameter and approximately 30 cm height was packed at a flow rate of 6 ml/min. The column was equilibrated with 3M ammonium sulfate in Tris – EDTA buffer pH 7.4. The sample was loaded at a flow rate of 2 ml/min. The plasmid was bound to the column at 3M ammonium sulfate. The column was then washed with 2-3 bed volumes with a 3M ammonium sulfate buffer solution. The column was then eluted with various concentrations of ammonium sulfate – 2.8M, 2.7M, 2.6M, 2.55M, 2.5M, 2.4M, 1M - using 2-3 column volumes. Peaks were observed in the 2.4M and 1M elutions. Agarose gel electrophoresis of the peaks is shown in Figure 6A. The gel indicates clear separation of the supercoiled and relaxed forms. The 2.4M elution contains the relaxed form, while the 1M elution contains the supercoiled DNA. The chromatogram is shown in Figure 6B. The results were further confirmed by an HPLC assay used to determine the percentage of the two forms (Table 7).

Within the limits of sensitivity of the assay, it was confirmed that the second peak contained 93% supercoiled form, whereas the starting material only contained 62% supercoiled form. These results were confirmed by subsequent experiments where 2.3M and 2.2M elutions did not provide the resolution, and the 2.4M elution repeatedly provided significant removal of the relaxed form, thereby enriching for the supercoiled form in the 1M elution. The separation accomplished using step elution is significant in large scale separations, which are more reliably performed using step elutions. This example clearly demonstrates the effective separation of supercoiled and relaxed forms of the plasmid using step elution of butyl hydrophobic interaction chromatography. In addition to this excellent separation, residual amount of RNA, protein, and endotoxin could be removed resulting in product that meets the specifications for gene therapy.

15 **Table 7**

Sample	% Supercoiled
Starting material	62
2.4M Elution	8
1M Elution	93

Example 8: Separation of the supercoiled and relaxed forms of the plasmid DNA using Hexyl Hydrophobic Interaction Chromatography – Gradient Elution Long column

E. coli cells harboring the plasmid pE1A-K2 were grown, and lysed using chemical methods, and clarified through filtration methods, as described above. Gross purification of the plasmid DNA to eliminate major contaminants such as endotoxin, RNA, protein, chromosomal DNA, etc. was performed using butyl hydrophobic interaction chromatography, where, at a

concentration of 2M Ammonium sulfate, the plasmid DNA flows through the column while the contaminants bind to the column (see, for example, Example 1 above). The flow through containing the plasmid DNA was dialyzed and processed on an anion exchange column that did not provide any additional purification. The elution from the Q column was diafiltered using a 30kD regenerated cellulose membrane. The dialyzed material was adjusted to 3M ammonium sulfate using solid ammonium sulfate (see above).

A Hexyl (Toyopearl Hexyl 650C – TosoHaas) column of 1 cm diameter and approximately 30 cm height was packed at a flow rate of 5 ml/min. The column was equilibrated with 3M ammonium sulfate in Tris – EDTA buffer pH 7.4. The sample was loaded at a flow rate of 2 ml/min. The plasmid was bound to the column at 3M ammonium sulfate. The column was then washed with 2-3 bed volumes with a 3M ammonium sulfate buffer solution. The column was then eluted with a gradient of ammonium sulfate concentration from 3M to 1M over 6 bed volumes. During the gradient elution, two peaks resulted, the first peak containing predominantly the relaxed form of the plasmid DNA, and the second peak containing predominantly the supercoiled form of plasmid DNA as evidenced in agarose gels of fractions (Figure 7A).

The chromatogram is shown in Figure 7B. Qualitatively, the second peak contained significantly higher proportion of supercoiled plasmid than the starting material based on agarose gel electrophoresis. Excellent resolution of the peaks were obtained, considering the fact that the bead size was 100 :m for the Hexyl, compared to 35 :m for the Butyl.

Example 9: Endotoxin removal using Butyl Hydrophobic Interaction Chromatography (using sodium chloride)

E. coli cells harboring the plasmid pE1A-K2 was grown, and lysed using chemical methods, and clarified through centrifugation methods. The supernatant was used for the experiment. The sample was purified through an anion exchange column (Q Hyper D – BIOSEPRA Inc.). A 2M sodium chloride elution from the column was used for this experiment. The sample was present in 50mM Tris 10mM EDTA pH 7.4 buffer with 2M NaCl. A Butyl HIC column (using Butyl 650S resin – TosoHaas) of diameter 1 cm and height 20 cm of approximately 10ml volume was packed and equilibrated with TE containing 2M sodium chloride. The sample was loaded at a flow rate of 2 ml/min. The flow through was collected, and samples were taken for analysis (DNA concentration, agarose gel, and endotoxin assay). Following the sample load, TE containing 2M ammonium sulfate was flowed through the column, collected and sampled. The column was subsequently washed with TE pH 7.4.

Table 8

Sample	DNA conc. (mg/ml)	Endotoxin EU/ml	Total Eunits EU	% Endotoxin	EU per mg of DNA
Load	0.27	642	16,050	100	2377
Wash	0.13	5	350	2	38

Endotoxin capacity per ml of resin: **1570 EU/ml**
 Endotoxin reduction in sample: **98 %**

Example 10: Small Scale Plasmid Purification with Butyl Hydrophobic Interaction Chromatography

Small-scale plasmid DNA purification is performed using commercially available kits, the most commonly known of which is a Qiagen's Miniprep kit. The methods described herein may be used for purification of plasmid DNA to provide several advantages over commercial
5 kits. The following example demonstrates the use of the hydrophobic interaction chromatography method of the present invention for purification of plasmid DNA on a small scale.

The starting material for purification was obtained through standard methods. Specifically, *E. coli* cells harboring plasmid of approximately 4.65
10 Kb size was grown in Luria Broth containing 100µg/ml of ampicillin at 37°C. The cells were harvested at an OD of 2.7. The cells were removed from the media through centrifugation. Subsequently, the cell pellet was resuspended in 50mM Tris-HCl, 10mM EDTA pH8.0. An equal volume of 200mM NaOH, 1% SDS solution was added, mixed well and incubated at room
15 temperature for 5 minutes. This step results in lysis of the cells, releasing the cell contents, including plasmid DNA. Neutralization solution consisting of 3.1M potassium acetate (pH 5.5) was added in equal (original) volume and mixed well. The neutralized lysate was then filtered through cheese cloth and filters to remove the precipitate. The clarified lysate was precipitated with
20 70% isopropanol (adding 2.1ml isopropanol per 3 ml of clarified lysate). The precipitate was separated through centrifugation and the pellet was washed with 70% ethanol, dried and dissolved in 10mM Tris-HCl, 0.1mM EDTA buffer, pH 8.0. This preparation was frozen at -20°C until use and was the starting material for the purification experiments.

25 A Butyl 650S column with a bed volume of 20 ml and bed height of 10 cm was packed in a 1.6cm diameter column (Pharmacia XK16/20) and equilibrated with 2.2M ammonium sulfate (AS) in 50mM Tris-HCl, 10mM EDTA (TE) buffer, pH 7.4. The sample for load was prepared by adding

solid ammonium sulfate to a final concentration of 2.2M. The sample was diluted with 2.2M AS in Tris – EDTA, pH 7.4 to 10 ml.

Purification conditions were designed to allow the plasmid DNA to be collected in the flow through and the contaminants were bound to the resin.

5 The sample was loaded at 2 ml/min and flow through was collected. The column was washed with 35 ml of 2.2M AS in TE buffer and collected as Wash 1(10 ml), Wash 2 (14.5 ml), and Wash 3 fractions (10ml). A peak resulted during the wash. The column was eluted with 55 ml of 1M AS in TE buffer, pH 7.4 and collected as 1M Wash 1 (10ml) and 1M Wash 2 (45ml). A
10 peak resulted during 1M AS elution. The column was eluted with 50 ml of USP – Purified Water. A peak resulted. The table below shows the total nucleic acid present in each of the fractions above. The concentrations were calculated based on the absorbance at 260nm (Conc. ($\mu\text{g/ml}$) = $A_{260} * 50$)

15 **Table 9**

Column fractions	Conc.	Mass
	($\mu\text{g/ml}$)	(μg)
Load	550.0	5503
Wash 1	7.6	76
Wash 2	40.4	607
Wash 3	5.0	50
Wash pool (Plasmid DNA)	20.9	733
1M elution	35.8	1611
Water elution	30.5	1523

An agarose gel electrophoresis of the samples were performed. Figure 8 shows a photocopy of the gel. The photograph of the gel shows the plasmid DNA in the Wash fractions (Lane 3, 4, 5). In comparison with the load
20 sample (Lane 2) no visible RNA is seen in the Wash fractions. The elution

fractions contain RNA as seen in Lanes 6 and 7. The endotoxin in the Wash pool was measured using a Kinetic QCL endotoxin assay. No endotoxin was detected in the sample at the sensitivity level of the assay, which was .005 EU/ml. The yield of plasmid was 733 µg from 100 ml of the culture which is similar to that obtainable with commercial kits.

* * * * *

The entire contents of references cited herein and below are incorporated in their entirety by reference.

Production of pharmaceutical-grade plasmid DNA, Magda Marquet, Nancy Horn, Jennifer Meek, Gregg Budahazi, U.S. Patent Number: 5,561,064

Concentration and size-fractionation of nucleic acids and viruses in porous media, Cole, Kenneth D., U.S. Patent Number: 5,707,850

Purification of plasmid DNA during column chromatography, Nancy Horn, Greg Budahazi, Magda Marquet, U.S. Patent Number: 5,707,812

I claim:

1. A method for purifying plasmid DNA from a mixture of same containing at least one host cell impurity comprising the following steps:
 - (a) forming a solution by adding sufficient salt to said mixture to allow selective binding of said at least one host cell impurity to a hydrophobic interaction media;
 - (b) contacting said solution containing plasmid DNA with said hydrophobic interaction media under conditions that said at least one impurity binds to the hydrophobic interaction media to form a complex; and
 - (c) collecting unbound plasmid DNA from said complex and hydrophobic interaction media;

wherein said method is conducted in the absence of solvents, detergents, glycols, hexamine cobalt, spermidine, and polyvinylpyrrolidone.

2. The method of claim 1 wherein the at least one impurity is selected from the group consisting of RNA, endotoxin, chromosomal DNA and protein.

3. The method for claim 1 wherein the at least one impurity is an endotoxin.

4. The method of claim 1 wherein the salt comprises an anion or cation selected from the group consisting of acetate, phosphate, carbonate, SO_4^{2-} , Cl^- , Br^- , NO_3^- , Mg^{2+} , Li^+ , Na^+ , K^+ and NH_4^+ .

5. The method of claim 4 wherein the salt is ammonium sulfate in a concentration range of 2M to 4M.

6. The method of claim 5 wherein ammonium sulfate is present at a concentration of about 2M.

7. The method of claim 1 wherein the solution comprises sodium salts in a concentration range of 2M to 4M.

8. The method of claim 7 wherein the sodium salt is sodium chloride.

9. The method of claim 8 wherein the sodium salt is sodium chloride in a concentration of about 2M.

10. The method of claim 1 wherein the pH of the solution has a range of about 6.8 to about 7.4.

11. The method of claim 1 wherein the pH of the solution is about 7.4.

12. The method of claim 1 wherein the hydrophobic interaction media comprises a chromatography support with pendent hydrophobic groups.

13. The method of claim 12 wherein said pendent groups are selected from the group consisting of C₃ to C₁₀ alkyl groups and mixtures thereof.

14. The method of claims 12 wherein the hydrophobic interaction media are selected from the group consisting of a methacrylate polymer or copolymer backbone bound to a least one of a propyl, butyl, hexyl, octyl, nonyl or decyl ligand.

15. The method of claim 14 wherein the media is at least one of a methacrylate ethylene glycol copolymer backbone or a cross-linked agarose backbone.

16. The method of claim 12 wherein the resin is in the form of bead in the size range of 15 to 100 μm .

17. A method of separating supercoiled plasmid DNA from a mixture of supercoiled plasmid DNA and relaxed plasmid DNA and, optionally, at least one host cell impurity comprising the following steps:

(a) forming a solution by adding a salt to the mixture of supercoiled plasmid DNA and relaxed plasmid DNA and, when present, said at least one host cell impurity;

(b) contacting the solution with a hydrophobic interaction media under a first conditions where both the supercoiled plasmid DNA and relaxed plasmid DNA bind to the hydrophobic interaction media to form a bound first mixture;

(c) altering the first conditions surrounding the bound first mixture to a second conditions to remove relaxed plasmid DNA from bound first mixture to form separate components containing a second bound mixture and relaxed plasmid DNA; and

(d) modifying the second conditions surrounding the said bound second mixture to a third conditions to remove supercoiled plasmid DNA from said second bound mixture to form separate components containing hydrophobic interaction media and supercoiled plasmid DNA.

18. The method of claim 17 wherein the at least one host cell impurity is selected from the group consisting of RNA, endotoxin, chromosomal DNA and protein.

19. The method for claim 17 wherein the at least one host cell impurity is an endotoxin.

20. The method of claim 17 wherein the hydrophobic interaction media comprises a chromatography support with pendent hydrophobic groups.

21. The method of claim 20 wherein said pendent groups are selected from the group consisting of C₃ to C₁₀ alkyl groups.

22. The method of claim 20 wherein the hydrophobic interaction media is selected from the group consisting of a methacrylate polymer or copolymer backbone bound to a least one of a propyl, butyl, hexyl, octyl, nonyl, or a mixture of these as ligands.

23. The method of claim 20 wherein the media is at least one of a methacrylate ethylene glycol copolymer backbone or a cross-linked agarose.

24. A method of claim 20 wherein the media is a resin in the form of beads in the size range of 15 to 100 μ m.

25. The method of claim 17 wherein the salt comprises an anion or cation selected from the group consisting of acetate, phosphate, carbonate, SO₄²⁻, Cl⁻, Br⁻, NO₃⁻, Mg²⁺, Li⁺, Na⁺, K⁺ and NH₄⁺.

26. The method of claim 25 wherein the salt is ammonium sulfate in a concentration range of 2.5M to 4M.

27. The method of claim 17 wherein the first conditions comprises equilibrating said media with a salt solution containing ammonium sulfate which is present in a concentration range of about 2.5M to 4M.

28. The method of claim 17 wherein the second conditions comprises washing the media with a salt solution containing ammonium sulfate in a concentration of about 2.35M to about 2.45M.

29. The method of claim 17 wherein the said third conditions comprises washing said second bound mixture with a salt solution containing ammonium sulfate in a concentration of about 1M to 2.3M.

30. A method of separating endotoxin from plasmid DNA comprising contacting a mixture of endotoxin and plasmid DNA with a hydrophobic interaction media under conditions where said endotoxin binds said hydrophobic interaction media to form a complex and separating said plasmid DNA and said complex.

31. The method of claim 30 wherein the salt comprises an anion or cation selected from the group consisting of acetate, phosphate, carbonate, SO_4^{2-} , Cl^- , Br^- , NO_3^- , Mg^{2+} , Li^+ , Na^+ , K^+ and NH_4^+ .

32. The method of claim 30 wherein said mixture further comprises an ammonium salt in a concentration range of 1.5 to 4M.

33. The method of claim 32 wherein said ammonium salt is ammonium sulfate which is present at a concentration of about 2M.

34. The method of claim 30 wherein the hydrophobic interaction media comprises a chromatography support with pendent hydrophobic groups.

35. The method of claim 34 wherein said pendent groups are selected from the group consisting of C₃ to C₁₀ alkyl groups.

36. The method of claim 34 wherein the hydrophobic interaction media is selected from the group consisting of a methacrylate polymer or copolymer backbone bound to a least one of a propyl, butyl, hexyl, octyl, nonyl, or a mixture of these as ligands.

37. The method of claim 34 wherein the media is at least one of a methacrylate ethylene glycol copolymer backbone or a cross-linked agarose.

38. A method of claim 34 wherein the media is a resin in the form of beads in the size range of 15 to 100 μm .

39. The method of claim 30 wherein said mixture has a pH in the range of about 6.8 to about 7.4.

40. The method of claim 35 wherein the pH is about 7.4

41. A method of separating supercoiled plasmid DNA from relaxed plasmid DNA comprising contacting a mixture of supercoiled plasmid DNA and relaxed plasmid DNA with a hydrophobic interaction media under a first conditions where both the supercoiled plasmid DNA and the relaxed plasmid DNA bind to said hydrophobic interaction media to form a bound first mixture, altering said first conditions surrounding the bound first mixture to a

second conditions to remove said relaxed plasmid DNA from said bound first mixture to form separate components containing a second bound mixture and said relaxed plasmid DNA, and modifying the second conditions surrounding said second bound mixture to a third conditions to remove said supercoiled plasmid DNA from said second bound mixture to form separate components containing said hydrophobic interaction media and said supercoiled plasmid DNA.

42. The method of claim 41 wherein said hydrophobic interaction media comprises a chromatographic support with pendent hydrophobic groups.

43. The method of claim 42 wherein said pendent hydrophobic groups are selected from the group consisting of C₃ to C₁₀ alkyl groups and mixtures thereof.

44. The method of claim 41 wherein said hydrophobic resin is a methacrylate polymer or copolymer backbone bound to at least one of a propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl ligand.

45. The method of claim 44 wherein said resin is at least one of a methacrylate and ethylene glycol copolymer backbone or a cross-linked agarose.

46. The method of claim 41 wherein said resin is in the form of beads ranging in size from 35 to 100 μm .

47. The method of claim 41 wherein said first conditions comprises equilibrating said mixture and media with a salt solution containing ammonium sulfate in a concentration range of about 2.5 M to about 4 M.

48. The method of claim 47 wherein said second conditions comprises washing said first bound mixture with a salt solution containing ammonium sulfate in a concentration of about 2.35 M to about 2.45 M.

49. The method of claim 48 wherein said third conditions comprises washing said second bound mixture with a salt solution containing ammonium sulfate in a concentration of about 1 M to about 2.3M.

50. The method of any one of claims 17 and 41 wherein said altering and said modifying are combined in a continuous process comprising gradient elution of said relaxed plasmid DNA and supercoiled plasmid DNA by mixing said bound first mixture with an ammonium sulfate containing salt solution with a continuously varying concentration of ammonium sulfate, said concentration varying from about 3M to about 1 M ammonium sulfate, and said relaxed plasmid DNA is collected in a first eluted volume and said supercoiled plasmid DNA is collected in a second eluted volume.

51. The method of claim 41 wherein said separate relaxed plasmid DNA component and said separate supercoiled plasmid DNA are collected and isolated.

52. A method for the enriching the amount of supercoiled DNA relative to relaxed DNA in a mixture thereof, the method comprising:

(1) interacting the mixture containing supercoiled DNA and relaxed DNA with a hydrophobic interactive media comprising an alkyl moiety under ionic conditions wherein the supercoiled DNA preferentially binds to the hydrophobic interactive media;

(2) treating the hydrophobic interactive media containing the relaxed and supercoiled DNA under ionic conditions that allow the preferential removal of the relaxed DNA; and

(3) eluting the supercoiled DNA from the hydrophobic interactive media.

53. A method for removing lipopolysaccharide (LPS) from a composition containing DNA, the method comprising:

(1) interacting the mixture comprising the DNA and LPS with a hydrophobic interactive media comprising an alkyl moiety, wherein the interacting is under ionic conditions where the LPS preferentially binds to the hydrophobic interactive media relative to the DNA; and

(2) treating the hydrophobic interactive media containing the DNA and LPS with ionic conditions that allow the selective removal of the DNA.

1/6

Fig. 1

METHOD FOR SEPARATION OF SUPERCOILED PLASMID DNA FROM RELAXED PLASMID DNA







Fig. 2


2/6

Butyl HIC resin bead**Hexyl HIC resin bead****Octyl HIC resin bead**



3/6

Fig. 3

Method for endotoxin removal from plasmid DNA solutions





4/6

**Fig. 4****Fig. 5**

SUBSTITUTE SHEET (RULE 26)

5/6

**Fig. 6****Fig. 8**

6/6




Fig. 7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/14527

A. CLASSIFICATION OF SUBJECT MATTER		
IPC(7) :C07H 21/00, 21/04 US CL :536/25.40		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/25.40		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) File HCAPLUS, BIOSIS, MEDLINE, EMBASE, SCISEARCH, LIFESCI, WPIDS.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	WO 99/29832 A1 (GENZYME CORPORATION) 17 June 1999, see entire document.	1-53
A	US 5,622,960 A (POMMIER et al.) 22 April 1997, see entire document.	1-53
Y	COLOTE et al. Analysis and Purification of Plasmid DNA by Reversed-Phase High-Performance Liquid Chromatography. Analytical Biochemistry. April 1986, Vol. 154, No. 1, pages 15-20, see entire document.	17-52
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family	
Date of the actual completion of the international search 09 AUGUST 2000		Date of mailing of the international search report 28 AUG 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Lawrence Eric Crane</i> LAWRENCE ERIC CRANE Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/14527

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database HCAPLUS, Accession No. 1999:688475 ,DIOGO et al. Separation and Analysis of Plasmid Denatured Forms Using Hydrophobic Interaction Chromatography. Analytical Biochemistry. 1999, Vol. 275, No. 1, pages 122-124, only abstract supplied, see entire abstract.	1-53
Y	ONISHI et al. An Assay Method for DNA Topoisomerase Activity Based on Separation of Relaxed DNA from Supercoiled DNA Using High-Performance Liquid Chromatography. Analytical Biochemistry. April 1993, Vol. 210, No. 1, pages 63-68, see entire document.	17-52
Y	GREEN et al. Purification of Nucleic Acid-Based Pharmaceuticals with Polyflo(TM) Resin. Clinical Chemistry. 17-19 December 1994, Vol. 40, No. 12, page 2335, see abstract bridging columns 1 and 2.	1-53
Y	WEINER et al. Plasmid Purification Using Reverse-Phase High Performance Liquid Chromatography Resin PRP. Nucleic Acids Research. 25 August 1988, Vol. 16, No. 16, page 8185, see entire document.	1-17 and 53